First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.
Ivan Barrera, Petr Kavan(Université Paris Cité), Shahid Ahmed(Emory University), Petr Novotný(Charles University), Jill J. Ranger(Jewish General Hospital), Neha Papneja(McGill University), Abhishek Papneja, Gerald Batist(Jewish General Hospital)
Cited by 0
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301